[HTML][HTML] Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system
M Strzelec, J Detka, P Mieszczak… - Frontiers in …, 2023 - frontiersin.org
In recent years, there has been a tremendous development of biotechnological,
pharmacological, and medical techniques which can be implemented in the functional …
pharmacological, and medical techniques which can be implemented in the functional …
[HTML][HTML] Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies
GE Thorlacius, A Björk… - Nature Reviews …, 2023 - nature.com
In primary Sjögren syndrome (pSS), chronic inflammation of exocrine glands results in tissue
destruction and sicca symptoms, primarily of the mouth and eyes. Fatigue, arthralgia and …
destruction and sicca symptoms, primarily of the mouth and eyes. Fatigue, arthralgia and …
[HTML][HTML] Autoimmune pancreatitis: from pathogenesis to treatment
EC Nista, SS De Lucia, V Manilla, T Schepis… - International journal of …, 2022 - mdpi.com
Autoimmune pancreatitis (AIP) is a rare disease. The diagnosis of AIP is difficult and should
be made by a comprehensive evaluation of clinical, radiological, serological, and …
be made by a comprehensive evaluation of clinical, radiological, serological, and …
ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus
T Manolakou, D Nikolopoulos, D Gkikas, A Filia… - Science …, 2022 - science.org
B cells orchestrate autoimmune responses in patients with systemic lupus erythematosus
(SLE), but broad-based B cell–directed therapies show only modest efficacy while blunting …
(SLE), but broad-based B cell–directed therapies show only modest efficacy while blunting …
[HTML][HTML] Epigenetic alterations in immune cells of systemic lupus erythematosus and therapeutic implications
DE Adams, WH Shao - Cells, 2022 - mdpi.com
Systemic lupus erythematosus (SLE) is an autoimmune disorder that is characterized by
autoantibody production and dysregulated immune cell activation. Although the exact …
autoantibody production and dysregulated immune cell activation. Although the exact …
[HTML][HTML] Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
KA Kirou, M DallEra, C Aranow, HJ Anders - Frontiers in Immunology, 2022 - frontiersin.org
Treatment of systemic lupus erythematosus (SLE) currently employs agents with relatively
unselective immunosuppressive properties. However, two target-specific biological drugs …
unselective immunosuppressive properties. However, two target-specific biological drugs …
Povetacicept, an enhanced dual APRIL/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell …
LS Evans, KE Lewis, D DeMonte… - Arthritis & …, 2023 - Wiley Online Library
Objective Dysregulated APRIL/BAFF signaling is implicated in the pathogenesis of multiple
autoimmune diseases, including systemic lupus erythematosus and lupus nephritis. We …
autoimmune diseases, including systemic lupus erythematosus and lupus nephritis. We …
The Oxysterol Receptor EBI2 Links Innate and Adaptive Immunity to Limit IFN Response and Systemic Lupus Erythematosus
F Zhang, B Zhang, H Ding, X Li, X Wang… - Advanced …, 2023 - Wiley Online Library
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with abnormal
activation of the immune system. Recent attention is increasing about how aberrant lipid and …
activation of the immune system. Recent attention is increasing about how aberrant lipid and …
[HTML][HTML] Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021
AC Martins, MY Oshiro, F Albericio, BG de la Torre… - Biomedicines, 2022 - mdpi.com
Despite belonging to a relatively new class of pharmaceuticals, biological drugs have been
used since the 1980s, when they brought about a breakthrough in the treatment of chronic …
used since the 1980s, when they brought about a breakthrough in the treatment of chronic …
[HTML][HTML] Current treatment approach, emerging therapies and new horizons in systemic lupus erythematosus
P Athanassiou, L Athanassiou - Life, 2023 - mdpi.com
Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is
characterized by extreme heterogeneity with a variable clinical course. Renal involvement …
characterized by extreme heterogeneity with a variable clinical course. Renal involvement …